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ABSTRACT  
Background: The prognostic value of lymphovascular invasion (LVI) in breast cancer (BC) 
has been demonstrated in several independent studies. However, identification of driver 
molecules for LVI remains a challenging task. Large-scale transcriptomic profiling of 
histologically validated LVI can potentially identify genes that regulate LVI. Methods: 
Integrative bio-informatics analyses of the METABRIC study were performed utilising a 
subset of strictly defined LVI using histological and immunohistochemical (IHC) criteria. 
ARHGAP18 was amongst the top differentially expressed genes between LVI+ and LVI- BC 
with a 1.8 fold change. The prognostic impact of ARHGAP18 gene expression was assessed 
in the METABRIC dataset (n=1980) and externally validated using the online BC gene 
expression datasets utilising bc-GenExMiner v4.0 (n=2016). Subsequently, ARHGAP18 
protein expression was assessed on a large cohort of invasive BC (n=959) with long term 
follow-up using IHC. Results: Pooled analysis of ARHGAP18 mRNA expression showed 
that overexpression was associated with better outcome (p<0.001, Hazard ratio (HR) =0.82, 
95%CI 0.75-0.90). ARHGAP18 protein was expressed in the cytoplasm and nuclei of the 
tumour cells and its expression was positively associated with good prognostic variables. 
Lack of cytoplasmic expression showed associations with LVI (p=0.006), epithelial-
mesenchymal transition and the HER+ subtype (p=0.01). Loss of nuclear expression was 
associated higher grade, HER2+ and high Ki67LI (p=0.001). Cytoplasmic and nuclear 
expression showed a positive association with improved survival independent of other 
variables (P =0.01, HR = 0.74, 95%CI 0.60-87). Conclusions: ARHGAP18 expression at 
transcriptomic and protein levels is associated with improved patients’ outcomes whose 
deregulation may play a role in tumour progression and the development of LVI in BC. 
Further assessment of its potential therapeutic value in BC is warranted.   
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INTRODUCTION 
Lymphovascular invasion (LVI), is an indicator of metastatic potential and poor outcome in 
breast cancer (BC) (Altman & Bland, 1994; Choi et al, 2003; Debled et al, 2010; Lauria et al, 
1995; Lee et al, 1990; Quinlan, 1993; Song et al, 2011; Truong et al, 2005; Ugras et al, 
2014).  In a previous study (Quinlan, 1993) we have demonstrated that in a lymph node 
negative BC cohort, LVI could be used as a high-risk criterion conferring survival 
disadvantage equivalent to that provided by involvement of one or two lymph nodes and to 
that provided by one higher size category (pT1 to pT2) (Quinlan, 1993). Despite its 
recognised prognostic roles, the molecular mechanisms underlying the development of LVI 
in breast cancer and genes driving this process that could be used as potential therapeutic 
targets remain largely unknown [reviewed in (Aleskandarany et al, 2015). This is related not 
only to the complexity of the mechanisms involved in the development of LVI as part of the 
invasion-metastasis process and the complex interaction between tumour cells and their 
microenvironment but also due to the difficulty in studies’ design and the subjectivity of 
identification of true LVI negative and LVI positive BC. Here we hypothesised that large-
scale transcriptomic and genomic profiling of a cohort with strictly defined LVI status could 
potentially yield candidate key/driver genes. This approach is likely to narrow down the 
number of potential genes that can be further investigated using in vitro and in vivo assays 
models with the aim of identifying novel therapeutic targets.        
In this study, the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) data was used for exploring genes associated with LVI in invasive BC through 
extensive genome-wide analysis of gene expression and copy number aberrations (CNAs) 
(Curtis et al, 2012). LVI was defined using strict criteria with the aid of 
immunohistochemistry. Genes with significant differential expression were ranked according 
to the strength of their association with LVI. The CNAs of these genes were determined. One 
of the top genes that is currently gaining interest as a therapeutic target (Rao et al, 2015a), 
showed differential expression together with CNAs was the Rho-GTPase activating-protein 
18 (ARHGAP18). The prognostic impact of ARHGAP18 gene expression was externally 
validated using online BC gene expression datasets. Protein expression of ARHGAP18 was 
assessed on a large clinically-annotated cohort of invasive BC with long term follow-up using 
immunohistochemistry. The association between ARHGAP18 and LVI as well as 
clinicopathologic criteria and patients’ outcome were explored.   
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MATERIALS AND METHODS 
A: Gene identification using METABRIC Cohort 
To identify putative LVI driver genes, the METABRIC cohort data was exploration as the 
regard the gene expression and CNA between cases with definite LVI and cases with no 
evidence of LVI. Details of tissue processing, analysis and interpretation of the findings of 
the METABRIC study were previously described (Curtis et al, 2012). Briefly, the extracted 
and purified DNA probes were hybridised to Affymetrix SNP 6.0 arrays (Affymetrix, Santa 
Clara, CA) at AROS Applied Biotechnology (Aarhus, Denmark). The Illumina Totalprep 
RNA amplification kit (Ambion, Warrington, UK) was used, and then hybridised onto 
Illumina Human HT-12 v3 Expression Beadchips from the same manufacturer. For this 
purpose, the discovery set formed of cases from Nottingham primary series of invasive BC 
included in the METABRIC study (n= 328). Tumours in this discovery set were treated using 
standardised methods of specimen fixation, sampling, and processing as previously described 
(Rakha et al, 2012). The clinicopathological data including LVI status, axillary nodal status 
and other variables were available. The LVI status of these cases was determined using a set 
of criteria as follows: cases were defined as LVI positive (LVI+) when LVI was reported in 
routine practice as positive based on H&E sections of the whole tumours and LVI was 
confirmed using immunohistochemistry (IHC) using CD34 and/or D2-40 (Rakha et al, 2012) 
on one full-face tumour section from the surgical specimens. LVI negative (LVI-) cases were 
defined by negativity of LVI on both H&E sections and IHC. Importantly, cases in the 
discovery set with positive lymph nodes in the LVI- subgroup were excluded to avoid bias 
caused by potentially undetectable foci of LVI in the primary tumour.  This discovery set was 
used to identify genes differentially expressed between the two LVI subgroups that are likely 
to be related to LVI. The validation set (Addenbrookes cases; n = 914 cases) set was used to 
validate the expression of the differentially expressed genes, to ensure that genes were 
differentially expressed in both the Nottingham and Addenbrookes cohorts. To test for 
genes/transcripts significantly differentially expressed between LVI+ and LVI- cases, a 
supervised differential gene expression analysis approach of gene expression data was 
followed. This was performed using the Linear Model for Microarray and RNA-seq data 
(LIMMA) software package that is compatible with the Affymetrix data. The Affymetrix 
SNP 6.0 array data was further analysed for CNAs of each transcript in the list of top 
associated genes with LVI using Affymetrix SNP6 Copy Number Inference Pipeline (Cancer 
Genomics Computation Analysis group of the Broad Institute, USA). The top differentially 
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expressed genes were ranked based on their p value of association with LVI. Subsequently 
the CNAs of the top differentially expressed genes were determined.  Of the top 5 
differentially expressed genes, ARHGAP18 was identified.  
B: ARHGAP18 gene expression 
ARHGAP18 gene expression was evaluated in the METABRIC cohort of 1,980 breast cancer 
samples (Curtis et al, 2012). In this cohort, patients with ER positive and/or lymph node 
negative tumours did not receive adjuvant chemotherapy, whilst those with ER negative 
and/or lymph node positive tumours received adjuvant chemotherapy. Dichotomisation of 
ARHGAP18 mRNA expression was performed at the median mRNA expression of the 
studied cohort.  
C: External validation  
To further assess the prognostic significance of ARHGAP18 mRNA expression, bc-
GenExMiner v4.0 (Breast Cancer Gene-Expression Miner v3.0) online dataset 
(http://bcgenex.centregauducheau.fr) was used. This is composed of two statistical mining 
modules; the "prognostic module", offering the possibility to evaluate the in vivo prognostic 
impact of candidate genes in breast cancer, and the "correlation module", to compute 
correlation coefficients between gene expressions or to find lists of correlated genes in BC. 
The prognostic module was in this external validation, where Cox model, Kaplan–Meier and 
forest plots were performed (Jezequel et al, 2012). The prognostic significance was used as 
LVI status was not available for these cohorts. 
D: ARHGAP18 protein expression  
ARHGAP18 protein expression was assessed in formalin-fixed paraffin-embedded tissue 
samples from BC cases enrolled into the Nottingham Tenovus Breast Carcinoma Series: a 
well-characterised series of primary operable invasive BC presenting between 1987 and 1998 
at Nottingham City Hospital (n=959). Clinical and pathological data had been recorded and 
patients’ outcome data is regularly updated and prospectively maintained. Outcome data 
recorded included survival status, mean survival in months, recurrence of disease (including 
distant metastases) and cause of death.  Disease free interval (DFI) was defined as months 
from date of primary surgery to appearance of local, regional, or distant recurrence, Breast 
cancer specific survival (BCSS) was defined as months from primary surgery until breast 
cancer specific death and time to distant metastasis (distant metastasis-free interval, DMFI) 
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was defined as months from primary surgery to occurrence of first distant 
metastasis/recurrence. Adjuvant therapy was based upon tumour prognostic and predictive 
factors including the Nottingham Prognostic Index (NPI), lymph node (LN) status, 
menopausal status and ER positivity/negativity and included hormonal therapy and CMF 
(cyclophosphamide, methotrexate and 5-Flourouracil).  
Expression of a large number of molecular biomarkers relevant to BC tumorigenesis and 
progression including Oestrogen Receptor (ER), Progesterone Receptors (PR), Human 
Epidermal Growth Factor Receptor 2 (HER2), p53, Ki67, and others have been previously 
studied (Abd El-Rehim et al, 2005). The tumours were subtyped into luminal 
(ER+/PR+/HER2-), HER2+, and triple negative (PR-/ER-/HER2-) subtypes (Rakha et al, 
2009).  Table 1 summarises the clinicopathological data of this cohort. The median and mean 
age of the study population was 54 years (range: 24-70). The median overall survival in 
months was 168 months while the median DFI was 109 month. This work was approved by 
Nottingham Research Ethics Committee 2 under the title: Development of a molecular 
genetic classification of breast cancer. All tissue samples included in this study were from 
patients who were consented prior to inclusion in the study cohort.  
Validation of primary antibody specificity using Western Blotting:  
Prior to IHC, the specificity of the anti-ARHGAP18 antibody (ab175970, Abcam, UK) was 
validated using Western blotting performed on whole cell lysates of high expressor cells of 
ARHGAP18 mRNA according to manufacturer’s protocol. For this purpose, lysates of human 
cervical cancer (HeLa CCL-2, American Type Culture Collection (ATCC), USA) cell lines, 
and human breast adenocarcinoma (MDA-MB-231, ATTC HTB-26, USA) cell lines, were 
used. This was performed using 1:1000 dilution of the primary antibody (ab175970, Abcam, 
UK), and 1:15,000 of the horseradish peroxidase (HRP) labelled secondary anti-rabbit 
antibody, with β-actin (diluted 1:2000) used as a loading control. BSA was used for blocking. 
ECL was used to visualise the membrane as previously described (Mruk & Cheng, 2011). 
The images were developed via chemiluminescence using an Odyssesy Fc (Li-cor 
Bisosciences, U.S.A).   
IHC: Heat assisted antigen retrieval was performed in accordance to the manufacturer 
recommendations (citrate buffer pH 6.0 at 1000W for 20 minutes using microwave). The 
Novolink Max Polymer Detection System was used to visualise the reaction (RE7280-k 
Leica, Germany). Endogenous peroxidase activity was blocked by the addition of a 
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peroxidase block (Novolink Peroxidase Block) for 5 minutes. Non-specific binding of the 
primary antibody, post primary block (Novolink Protein block) was used. The slides were 
washed and incubated with the anti-ARHGAP18 primary antibody (ab175970, Abcam, UK, 
diluted 1:75 in Bond Primary Antibody Dilutent, Leica, Germany), for 30 minutes at room 
temperature (RT). This working dilution was chosen based on repeated attempts of 
optimisation using different dilutions, guided by the manufacturer’s recommendation, in 
order to achieve specific staining with minimal background. The positive control, β2 
microglobulin (Polyclonal Rabbit Anti-Human Beta-2-Microglobulin, Dako, Denmark) was 
incubated at 1:2000 dilution. A DAB (3,3’-diaminobenzadine) in a buffered stabiliser 
solution (Novolink DAB Chromogen; 1:20 dilution), was added to the slides for 5 minutes. 
The slides were counterstained with haematoxylin for 6 minutes (Novolink Haematoxylin). 
Dehydration, clearing, mounting and cover-slipping were performed as previously described. 
Full-face tissue sections from 25 BC excision specimens were also stained for ARHGAP18 to 
assess for the distribution of staining to decide for TMAs suitability. Negative and positive 
controls (by omission of the primary antibody, and human liver tissues, respectively) were 
included in each staining run. 
Scoring of TMA Cores:  
Stained TMA slides were digitally scanned (NanoZoomer, Hamamatsu Photonics, Japan) to 
high resolution images and viewed by Aperio ImageScope (Aperio Technologies, UK) at 20x 
magnification. Cores/images were individually evaluated and assigned an ‘H-Score’ by 
identification of the percentage of the malignant cells that were stained (0-100) and the 
staining intensity (0 -negative, 1 -weak, 2 -moderate and 3 -strong), and the final H-Score 
was calculated as previously described (McCarty et al, 1985). Scoring was performed by a 
single observer (RS) and a subset of cases (20%) was scored by an independent observer 
(MA) to assess inter-rater reliability. All identifying patient information and clinical variables 
were completely anonymised during scoring.   
Statistical analysis  
The H-Scores were linked to anonymised patient codes to match all other variables with 
biomarker expression. Analysis was performed in the statistical software package SPSS (IBM 
SPSS statistics, Version 22). The data were exported to X-Tile (X-Tile Bioinformatics 
Software, Yale University, version 3.6.1) to determine an unbiased optimally significant cut 
off point based on patients’ outcomes. Kappa statistic was used to test scoring reproducibility 
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between observers (inter-observer agreement). Analyses were performed for nuclear and 
cytoplasmic H scores independently. Univariate analysis was performed using the chi-
squared test to evaluate the significance of the association between expression of the 
biomarkers and the clinicopathological parameters of the data, as well as other previously 
investigated biomarkers. Kaplan-Meier analysis was performed to assess BCSS and DFI 
survival differences. Multivariate Cox Regression analysis with adjustment of co-variates 
was fitted to test independence from standard prognostic factors. A P-value of <0.05 (two 
tailed) was considered significant.       
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RESULTS 
Gene identification using the METABRIC study 
Analysis of the METABRIC transcriptomic data in the discovery and validation sets revealed 
514 genes differentially expressed with regard to LVI status. These genes were ranked in 
order based on the p-value of expression. Biological functions of the top differentially 
expressed genes were also assessed using published literature. In addition, the CNAs of these 
genes was analysed to identify those genes whose expression was associated with their gene 
CNAs (cis acting). Of the top 5 genes that showed differential expression associated with 
CNAs with regard to LVI was ARHGAP18 and this gene was subject to further analysis in 
this study.    
Using the median expression as a cut-off point, high ARHGAP18 mRNA expression was 
significantly associated with variables of good prognosis including smaller size (p<0.04), 
early stage (p<0.001), tumours of tubular subtype (p<0.001) and HER2- tumours (p=0.029). 
When comparing the levels of ARHGAP18 mRNA expression in the intrinsic (PAM50) 
subtypes, significant differences were observed (p=0.006), with the HER2+ subtype showing 
the least expression levels. Similarly, significant difference in the expression levels were 
observed within the different METABRIC Integrative Clusters (p=0.021), with clusters 5 
(ERBB2 amplified) and cluster 9 (Luminal B subgroup) showed the least ARHGAP18 mRNA 
expression. A trend towards significantly improved patients’ survival (p=0.082) in 
ARHGAP18 mRNA over-expression was also identified.   
ARHGAP18 mRNA expression levels in the external validation cohorts  
The prognostic impact of ARHGAP18 mRNA expression was subsequently assessed using 
bc-GenExMiner v4. (Breast Cancer Gene-Expression Miner v4) online dataset as external 
validation cohorts (n= 21 datasets, 4,177 patients). Of these, 12 datasets provided information 
on DMFI for ARHGAP18 mRNA expression. As shown in the Forest plot (Supplementary 
Figure 1), 4/12 studies showed high ARHGAP18 mRNA expression was significantly 
associated with improved DMFI, however, the remaining 8 studies did not show significant 
associations. When the data was pooled together (n=2,016), high ARHGAP18 mRNA 
expression was significantly associated with longer DMFI (p<0.001, HR=0.82, 95%CI 0.75-
0.90), Supplementary Figure 2. Interestingly, exhaustive prognostic analysis; which permits 
to screen the prognostic impact of ARHGAP18 mRNA on all possible combinations of 
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population, showed significantly improved outcome of patients in 9 out of 18 studies using 
all possible combinations, Supplementary Table 1. 
Immunohistochemical expression of ARHGAP18  
Validation of the antibody specificity using Western blot showed a single specific band at the 
predicted size (75 kDa) of ARHGAP18 protein, confirming the specificity of the antibody, 
Figure 1A. Full-Face sections stained with ARHGAP18 antibody showed homogenous 
staining distribution throughout stained sections, therefore, validating the use of TMA. IHC 
expression showed ARHGAP18 protein was localised in the nuclei and cytoplasm of tumour 
cells with varying intensities, Figure 1B, C &D.  In addition, positivity was observed in the 
cells of ductal carcinoma in situ and in the normal ductal epithelial cells entrapped in some 
cores. Overall, the expression was reduced in some invasive tumours compared to the cells of 
the in situ component or the normal ductal cells.  
Cases re-scored by an independent observer showed a very good (Kappa = 0.83) agreement 
between the two scorers. The H-Scores of both nuclear and cytoplasmic expression did not 
follow normal distribution. X-Tile determined optimal cut-off values as H-Sscore 140 for 
cytoplasmic staining, and 65 for nuclear staining. At these cut-offs, 848/959 (88.4%) cases 
showed negative/low nuclear expression and 111/959 (12.6%) showed positive/high nuclear 
expression. Cases with cytoplasmic staining were dichotomised as 784/959 (81.8%) cores 
negative/low expression and 175/959 (18.2%) with positive/high expression.  
ARHGAP18 protein expression and clinicopathological variables 
Cytoplasmic expression of ARHGAP18 showed an inverse association with the LVI 
(p=0.006) and Nottingham Prognostic Index (NPI, p=0.010) (Table 2). Loss of its expression 
was associated with epithelial mesenchymal transition with loss of E-cadherin and 
overexpression of N-cadherin, and with HER2 overexpression. Consistent with mRNA 
expression, ARHGAP18 cytoplasmic protein expression showed an association with IHC 
defined molecular subtypes where it was less expressed in the HER2+ and TNBC classes 
(p=0.035) (Table 3). Nuclear expression of ARHGAP18 was associated with lower grade 
(p=0.022), with less mitotic counts and nuclear pleomorphism, smaller tumour size 
(p=0.002), the better prognostic NPI subgroup (p=0.001), histological types of excellent/good 
prognosis (p=0.002) but not with LVI (Table 4). Positive nuclear expression showed 
significant associations with HER2 negativity (p=0.003), negative/low Ki67 (p=0.001) 
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luminal-A subtype (p=0.001), and the negative/low expression of N-cadherin, TGF-β1, 
PIK3CA and CTEN (p<0.05) Table 5.  
Similar statistical associations were observed when the expression of ARHGAP18 was taken 
into account irrespective of the localisation (i.e. negative versus positive cytoplasmic or 
nuclear expression).   
Expression of ARHGAP18 patient outcome 
Increased cytoplasmic expression of ARHGAP18 was significantly associated with improved 
outcome in terms of longer BCSS (p=0.004) and DMFI (p=0.012), Figure 2. Using 
multivariate cox regression analysis, this association was independent of tumour size, tumour 
grade, nodal stage and BC molecular subtype (p=0.017, hazard ration (HR=0.68, 95%CI 
0.49-0.93, and p=0.031, HR=0.72, 95%CI=0.54-0.97, for BCSS and DMFI, respectively).  
High nuclear expression was also significantly associated with longer BCSS (p=0.001) and 
DMFI (p=0.003), Figure 3. Again, similar statistical associations with patients’ outcome were 
observed when the expression of ARHGAP18 was taken into account irrespective of the 
localisation. These associations were independent of the standard prognostic factors including 
tumour size, nodal stage and tumour grade using Cox proportional multivariate analysis 
(p=0.023, HR=0.62, 95%CI =0.41-0.94, and p= 0.047, HR=0.69, 95%CI=0.47-0.10, for 
BCSS and DMFI, respectively). 
 
DISCUSSION 
The ARHGAP genes encode a family of at least 32 members of RhoGAP proteins with 
variable functions (Katoh & Katoh, 2004). The downstream target of the ARHGAPs is the 
Rho GTPase protein family; therefore, they are logical candidates to investigate their roles in 
BC. Members of the Rho GTPase family have numerous cellular functions including 
maintenance and control of the actin cytoskeleton, angiogenesis, cell proliferation, 
differentiation, and survival (Peck et al, 2002). Consequently, deregulation of these proteins 
has been implicated in multiple types of tumours.  In this study and using an integrative bio-
informatics analysis of gene expression and CNA data associated with LVI coupled with 
strict defining criteria for definition of LVI in BC we have identified ARHGAP18 as one of 
the top differentially expressed genes and its expression was associated with its gene CNA. 
ARHGAP18 is located on chromosome 6q22.33 and is a member of the ARHGAP family 
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(Potkin et al, 2008). After confirmation of its prognostic value in the METABRIC cohort and 
in external validation series, we sought to assess the protein expression of ARHGAP18 in a 
large unselected annotated series of BC with long-term follow-up.  
Studies exploring the impact of tissue-based ARHGAP18 protein expression in cancers 
including BC are lacking and most of the studies so far were performed using in vitro tissue 
culture platform. In the current study, ARHGAP18 IHC staining was detected in the 
cytoplasm and in the nuclei of invasive BC cells with variable percent and intensity, in the 
cells of ductal carcinoma in situ and in the normal ductal epithelial cells. An overall tendency 
of reduced expression was observed in invasive tumours compared to the non-invasive and 
normal ductal cells, with the latter showing the highest expression; observations which may 
be denoting a tumour suppressor role.  
Cytoplasmic expression of ARHGAP18 showed significant negative association with LVI. 
Recently, Chang et al reported on roles of ARHGAP18 in limiting proangiogenic signalling 
and promoting vascular stability through limiting endothelial cell sprouting and stabilising 
junctional integrity (Rao et al, 2015b). Moreover, knockdown of ARHGAP18 has been 
recently reported to promote endothelial cells migration in scratch wound assay with a 
protrusive and irregular migratory front and disrupted cell junctions at the proximal edge of 
the leading cell (Chang et al, 2014). Sustained angiogenesis is one of the hallmarks of cancer 
and is essential for tumour progression. Moreover, in the current study, reduced expression 
was associated with high Ki67, epithelial mesenchymal transition with expression of N-
cadherin and TGFβ1 and reduced expression of E-cadherin.  Similar significance was also 
identified with nuclear expression, showing positive association with other prognostic 
variables and outcome. A large proportion of cases strongly expressing ARHGAP18 were of 
the excellent prognosis histological subtypes including tubular, invasive cribriform and 
mucinous carcinomas. Nuclear expression was also significantly associated with lower 
tumour grade, lower mitotic scores, less nuclear pleomorphism and smaller tumour size. Such 
associations suggest ARHGAP18 may be a marker of related to tumour differentiation.  
Investigations specifically pertaining to the subcellular localisation of ARHGAP18 are 
lacking. However, similar to findings of the current study with ARHGAP18 in breast cancer 
it has been reported that ARHGAP21 is localised both in the cytoplasm and nuclei of 
prostatic carcinoma (Barcellos et al, 2013) and nuclear and perinuclear localisation seen in 
glioblastoma-derived cell lines (Bigarella et al, 2009). We suggest ARHGAP18 might have a 
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similar trafficking from the cytoplasm, where synthesis occurs, to the nucleus, possibly upon 
occasion of tumorigenic changes.  
The associations of both nuclear and cytoplasmic ARGAP18 with the cadherin switch in the 
current data; E-cadherin loss and N-cadherin gain, as well as the negative association with the 
EMT triggers TGFβ1 and PIK3CA (Zhao et al, 2006), as well as the migration associated 
CTEN (Albasri et al, 2009), reflects its potential role in controlling cellular cytoskeletal 
dynamics and migration. The latter is attributed to the recognised roles of Rho GTPases in 
controlling the actin cytoskeleton. ARHGAP18 has been postulated to suppress the function 
of RhoA and cause a disruption in the production of stress fibres; contractile bundles of actin 
found in non-muscle cells (Maeda et al, 2011). These functions may suggest a mechanism 
through which ARHGAP18 is involved in limiting spread and metastasis of cancer cells 
therefore may provide some explanation for its good prognostic value.  
High ARHGAP18 mRNA expression within the METABRIC dataset was significantly 
associated with variables of good prognosis including the PAM50 and Integrative Clusters of 
good prognostic classes. Although analysis of the METABRIC study revealed a trend 
towards improved patients’ outcome in cases over-expressing ARHGAP18, pooled analysis 
of the publicly available datasets, using the bc-GenExMiner v4, showed significant 
association between ARHGAP18 expression and better outcome. Although gene expression 
data reflects the overall expression levels, they show concordance with our protein expression 
data where increased ARHGAP18 expression in both the nucleus and cytoplasm was 
significantly associated with better outcome.   
In conclusion, results presented herein suggest ARHGAP18 may be acting, directly or 
indirectly, as a putative metastasis suppressor gene, based on its association with favourable 
prognostic features including negative association with LVI and longer survival at both 
protein and mRNA expression levels. The general tumour suppressor effect probably 
indicates that the relationship to LVI is perhaps within a co-ordinated set of events related to 
multiple events in BC development and progression. They also indicate the validity of our 
approach to identify novel biomarkers associated with complex biological processes that are 
related not only to the investigative techniques but also on robust histological 
characterisation. Further investigation of this biomarker as well as other genes differentially 
expressed with regard to LVI is warranted to decipher the mechanism underlying its 
development and to identify potential therapeutic targets. 
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Figures and Tables legends  
Figures legends:  
Figure 1: A; Western blot of ARHGAP18 and the housekeeping Beta-actin. Western blotting 
performed on whole cell lysates of HeLa CCL-2 and MDA-MB-231 (lanes 1 & 2, 
respectively). Primary antibody (Anti-ARHGAP18, 1:1000 dilution), and of the HRP labelled 
secondary anti-rabbit antibody (1:15,000), with β-actin (1:2000, lanes 3 & 4) used as a 
loading control. The images were developed via chemiluminescence using an Odyssesy Fc 
(Li-cor Bisosciences, U.S.A). B, C &D: Immunohistochemical expression of ARHGAP18 in 
invasive BC: B, Negative, C: Invasive BC case showing positive cytoplasmic expression, and 
D: a case of invasive BC case showing both nuclear and cytoplasmic expression.   
 
 
Figure 2: Kaplan-Meier Plots of the association between cytoplasmic ARHGAP18 
expression and BCSS and time to distant metastasis during the follow-up period. 
 
 
 
Figure 3: Kaplan-Meier Plots of the association between nuclear ARHGAP18 
expression and BCSS and time to distant metastasis during the follow-up period. 
 
 
 
Supplementary Figure 1: Forest plot of 12 external validation datasets had data for 
ARHGAP18 mRNA expression.   
 
 
 
Supplementary Figure 2: Kaplan-Meier Plots of pooled ARHGAP18 mRNA expression 
data metastatic recurrence (MR) free survival 
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Tables legends:  
Table 1: Summary of Patient Demographics of The Nottingham Primary BC Series Used in 
This Study   
 
 
Table 2: Statistical Association of Cytoplasmic H-score Expression of ARHGAP18 and the 
Clinicopathological Parameters of the Studied Series 
 
 
Table 3: Statistical Association of Cytoplasmic H-score Expression of ARHGAP18 and the 
Expression of other Biomarkers 
 
 
 Table 4: Associations of Nuclear H-scores for ARHGAP18 in Relation to the 
Clinicopathological Parameters 
 
 
Table 5: Association of Nuclear ARHGAP18 Expression and the Expression of other 
Biomarkers 
 
Supplementary Table 1: All Subgroups defined by Different nodal, Oestrogen Receptor and 
Event Status Ordered by p-value (smallest to largest) for Prognostic Association of ARGAP18 
mRNA Expression Using bc-GenExMiner v4.0. MR  = metastatic recurrence. AE = any 
event. 
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Table 1: Summary of patient demographics of the Nottingham primary BC series used in this study   
 
Parameter Number (%) 
Age  
          ≤ 50 years  
          > 50 years 
          Median/mean  
 
367 (38.3) 
591 (61.6) 
54 
Menopausal Status 
          Premenopausal  
          Postmenopausal 
 
381 (39.7) 
                     577 (60.2) 
Tumour Grade  
          1 
          2 
          3 
 
129 (13.6) 
300 (31.6) 
                     521 (54.8) 
Pleomorphisms         
         1 
         2 
         3 
 
13 (1.4) 
314 (33.9) 
 599 (64.7) 
Tubule Formation  
         1 
         2 
         3 
 
45 (4.8) 
308 (33.3) 
 574 (61.9) 
Mitotic Figures         
         1 
         2 
         3 
 
267 (28.8) 
196 (21.2) 
 463 (50.0) 
Tumour Size 
          ≤ 2 cm  
          > 2 cm  
 
543 (56.6) 
404 (42.1) 
Axillary Nodal Stage          
          1 (Node negative) 
          2 (1-3 positive nodes) 
          3 (≥ 4 positive nodes) 
 
 
571 (59.5) 
304 (31.7) 
78 (8.1) 
Nottingham Prognostic Index (NPI) 
          Good NPI (<3.4) 
          Moderate NPI (3.41-5.4) 
          Poor NPI (≥5.4) 
 
247 (26.0) 
530 (55.7) 
174 (18.3) 
Histological tumour type 
          Ductal No Special Type (NST)  
          Tubular Mixed 
          Medullary (typical and atypical) 
          Lobular* 
          Excellent Prognosis Special Groups** 
          Mixed NST and Lobular 
          Mixed NST and other Special Type 
 
578 (62.3) 
158 (17.0) 
23 (2.5) 
73 (7.9) 
38 (4.1) 
39 (4.2) 
19 (2.0) 
LVI    Negative 
          Definite 
612 (65.2) 
327 (34.8) 
Distant Metastasis 
          Negative 
          Positive
 
 
567 (60.1) 
376 (39.2) 
Survival (month) 
          Overall Survival: Median/mean (Range) 
          DFI : Median/mean (Range) 
 
168/149.6 (1-308) 
109/100 (2-239) 
ER status        
         ER positive 
         ER negative 
 
271 (28.5) 
681 (71.5) 
PR status 
          PR positive 
          PR negative 
 
407 (43.8) 
522 (56.2) 
HER2 status 
          HER2 positive 
          HER2 negative 
 
786 (85.4) 
131 (13.2) 
Molecular Subtype 
          Luminal 
          HER2 positive 
          Triple Negative 
 
614 (65.9) 
131 (14.1) 
187 (20.0) 
Table 2: statistical association of cytoplasmic H score expression of ARHGAP18 and the 
clinicopathological parameters of the studied series 
 
 
  
 
Parameter  
ARHGAP18 Cytoplasmic 
Expression 
 
2 
 
 
P value 
Low  
No. (%) 
High  
No. (%)  
Patients’ Age      
≤ 50 yrs 290 (79.0) 77 (21.0)  
3.178 
 
 
0.075 
 > 50 yrs 
494 (83.6) 97 (16.4) 
Menopausal Status     
Premenopausal 303 (79.5) 78 (20.5)  
2.270 
 
0.132 
Postmenopausal 481 (83.4) 96 916.6) 
Grade     
1 98 (76.0) 31 (24.0)  
3.439 
 
0.179 
2 247 (82.3) 53 (17.7) 
3 432 (82.9) 89 (17.1) 
Mitotic Figures     
1 221 (82.5) 47 (17.5) 
1.713 0.425 2 154 (78.6) 42 (21.4) 
3 383 (82.7) 80 (17.3) 
Pleomorphisms     
1 8 (61.5) 5 (38.5)  
6.015 
 
0.049 2 249 (79.3) 65 (20.7) 
3 500 (83.5) 99 (16.5) 
Tubule Formation     
1 34 (75.6) 11 (24.4)  
5.147 
 
0.075 2 242 (78.6) 66 (21.4) 
3 482 (84.0) 92 (16.0) 
Axillary nodal stage     
1 458 (80.2) 113 (19.8)  
2.900 
 
0.235 
2 258 (84.9) 46 (15.1) 
3 64 (82.1) 14 (17.9) 
Tumour size     
≤ 2 cm 437 (80.5) 106 (19.5)  
1.581 
 
0.209 
> 2 cm 338 (83.7) 66 (16.3) 
NPI     
Good (<3.4) 195 (78.9) 52 (21.2)  
 
17.898 
 
 
0.010 Moderate (3.41-5.4) 
431 (81.3) 99 (18.7) 
Poor (≥5.41) 152 (87.4) 22 (12.6) 
Vascular Invasion     
Negative 485 (79.2) 127 (20.8)  
7.617 
 
0.006 
Definite 283 (86.5) 44 (13.5) 
Tumour type      
Ductal carcinoma No Special Type 
(NST)  
476 (82.4) 102 (17.6)  
 
 
 
7.914 
 
 
 
 
0.244 
Tubular mixed 125(79.1) 33(20.9) 
Medullary-like   21(91.3) 2 (8.7) 
Invasive lobular 63 (86.3) 10 (13.7) 
Excellent Prognosis Special Type** 26 (68.4) 12 (31.6) 
Mixed NST and lobular 32 (82.1) 7 (17.9) 
Mixed NST and other special type 16 (84.2) 169 (18.2) 
Table 3: Statistical association of cytoplasmic H score expression of ARHGAP18 and 
the expression of other biomarkers 
 
 
Parameter 
ARHGAP18 Cytoplasmic 
Expression 
Significance  
Low 
No. (%) 
High 
No. (%) 
2 
 
p  value 
ER     
Negative  227 (83.8) 44 (16.2)  
0.955 
 
0.328 Positive 552 (81.1) 129 (18.9) 
PR     
Negative 343 (84.3) 64 (15.7)  
2.962 
 
0.085 Positive 417 (79.9) 105 (20.1) 
HER2     
Negative 636 (80.9)  150 (19.1)  
5.391 
 
0.019 Positive 117 (89.3) 14 (10.7) 
Molecular Subtypes     
Luminal 492 (80.1) 122 (19.9)  
6.719 
 
0.035 HER2+ 117 (89.3) 14 (10.7) 
Triple Negative 157 (84.0) 30 (16.0) 
p53     
Negative 528 (82.2) 114 (17.8)  
0.081 
 
0.776 Positive 224 (81.5) 51 (18.5) 
Ki67     
Negative 179 (82.1) 39 (17.9)  
0.004 
 
0.951 Positive 435 (81.9) 96 (18.1) 
E-Cadherin   
  
Negative 284 (86.1) 46 (13.9)  
5.223 
 
0.023 Positive 448 (80.0) 112 (20.0) 
N-Cadherin    
  
Negative 147 (78.6) 40 (21.4)  
5.752 
 
0.019 Positive 440(86.1) 71 (13.9) 
TGF-β1   
  
Negative 274 (79.7) 70 (20.3) 
1.465 0.262 Positive 246 (83.4) 49 (16.6) 
PIK3CA   
  
Negative 129 (79.1) 34 (20.9) 
  
Positive 471 (83.1) 96 (16.9) 
1.334 0.247 CTEN   
Negative 31 (79.5) 8 (20.5) 
0.363 0.514 Positive 575 (83.2) 116 (16.8) 
Table 4: Associations of nuclear H scores for ARHGAP18 in relation to the 
clinicopathological parameters 
 
 
 
Parameter 
ARHGAP18 Nuclear Expression 
 
2  P value Low Expression 
No. (%) 
High 
Expression 
No. (%) 
Patients’ Age      
≤ 50 yrs 320 (87.2) 47 (12.8)  
0.585 
 
 
0.471 
 
> 50 yrs 525 (88.8) 66 (11.2) 
Menopausal Status     
Premenopausal 335 (87.9) 46 (12.1)  
0.047 
 
0.838 
Postmenopausal 510 (88.4) 67 (11.6) 
Grade     
1 103 (79.8) 26 (20.2)  
 
12.832 
 
 
0.002 2 262 (87.3) 38 (12.7) 
3 474 (91.0) 47 (9.0) 
Mitotic Figures     
1 222 (82.8) 46 (17.2)  
11.914 
 
0.003 2 176 (89.8) 20 (10.2) 
3 422 (91.1) 41 (8.9) 
Pleomorphisms     
1 10 (76.9) 3 (23.1)  
7.705 
 
0.021 2 267 (85.0) 47 (15.0) 
3 542 (90.5) 57 (9.5) 
Tubule Formation     
1 40 (88.9) 5 (11.1)  
3.441 
 
0.179 2 264 (85.7) 44 (14.3) 
3 516 (89.9) 58 (10.1) 
Axillary nodal stage     
1 496 (86.9) 75 (13.1)  
2.656 
 
0.265 2 275 (90.5) 29 (9.5) 
3 70 (89.7) 8 (10.3) 
Tumour size     
≤ 2 cm 464 (85.5) 79 (14.5)  
9.835 
 
0.002 
> 2 cm 372 (92.1) 32 (7.9) 
NPI     
Good (<3.4) 203 (82.2) 44 (17.8)  
 
13.748 
 
 
0.001 Moderate (3.41-5.4) 475 (89.6) 55 (10.4) 
Poor (≥5.4) 162 (93.1) 12 (6.9) 
Vascular Invasion     
Negative 531 (86.8) 81 (13.2)  
3.372 
 
0.066 
Definite 297 (90.8) 30 (9.2) 
Tumour type      
Ductal carcinoma No Special 
Type (NST) 
529 (91.5) 49 (8.5)  
 
 
 
 
21.170 
 
 
 
 
 
0.002 
Tubular mixed 136 (86.1) 22 (13.9) 
Medullary (typical and 
atypical) 
20 (87.0) 3 (13.0) 
Lobular* 59 (80.8) 14 (19.2) 
Excellent Prognosis Special 
Type** 
29 (76.3) 9 (23.7) 
Mixed NST and lobular 32 (82.1) 7 (17.9) 
Mixed NST and other special 
type 
14 (73.7) 5 (26.3) 
Table 5: Association of nuclear ARHGAP18 expression and the expression of other 
biomarkers 
 
 
 
 
Parameter 
ARHGAP18 Nuclear 
Expression 
 
Significance 
Low 
Expression 
No. (%) 
High 
Expression 
No. (%) 
2 p  value 
ER     
Negative 248 (91.5) 23 (8.5)  
3.702 
 
0.054 Positive 593 (87.1) 88 (12.9) 
PR     
Negative 369 (90.7) 38 (9.3)  
3.381 
 
0.066 Positive 453 (86.8) 69 (13.2) 
HER2     
Negative 683 (86.9) 103 (13.1)  
11.433 
 
0.003 Positive 127 (96.9) 4 (3.1) 
Molecular 
Subtypes 
    
Luminal 528 (86.0) 86 (14.0)  
 
13.522 
 
 
0.001 
HER2+ 127 (96.9) 4 (3.1) 
Triple Negative 169 (90.4) 18 (9.6) 
p53     
Negative 567 (88.3) 75 (11.7)  
0.032 
 
0.859 Positive 244 (88.7) 31 (11.3) 
Ki67     
Low 179 (82.1) 39 (17.9)  
10.599 
 
0.001 High 481 (90.6) 50 (9.4) 
E-cadherin      
Negative  299 (90.6) 31 (9.4)  
1.784 
 
0.182 Positive  491 (87.7) 69 (12.3) 
N-cadherin     
Negative  156 (83.4) 31 (16.6)  
10.828 
0.002 
Positive  470 (92.0) 41 (8.0) 
TGF-β1     
Negative  296 (86.0) 48 (14.0)  
6.870 
0.011 
Positive  273(92.5) 22 (7.5) 
PIK3CA     
Negative  126 (77.3) 37 (22.7)  
24.932 
< 0.001 
Positive  519 (91.5) 48 (8.5) 
CTEN   
  
Negative  29 (74.4) 10 (25.6) 
8.836 0.007 Positive  620 (89.7) 71 (10.3) 





